EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist.
EMEND, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin (see DOSAGE AND ADMINISTRATION).
Media Articles Related to Emend (Aprepitant)
Ovarian cancer oncogene found in 'junk DNA'
Source: Genetics News From Medical News Today [2014.09.09]
Over the years researchers have made tremendous strides in the understanding and treatment of cancer by searching genomes for links between genetic alterations and disease.
Nausea and Vomiting
Source: MedicineNet Anaphylaxis Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM
Published Studies Related to Emend (Aprepitant)
Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk
patients: a phase II randomized, double-blind placebo controlled trial. 
patients... CONCLUSIONS: Aprepitant did not lower incidence of post-ERCP pancreatitis in this
Randomized, double-blind, placebo-controlled, phase III cross-over study
evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3
receptor antagonist and dexamethasone in patients with germ cell tumors receiving
5-day cisplatin combination chemotherapy regimens: a hoosier oncology group
of cisplatin combination chemotherapy for testicular cancer... CONCLUSION: There was a significant improvement in CR rate with aprepitant
Randomized, double-blind comparison of oral aprepitant alone compared with
aprepitant and transdermal scopolamine for prevention of postoperative nausea and
and vomiting (PONV) treated with oral aprepitant with or without scopolamine... CONCLUSIONS: This trial evaluating the effectiveness of aprepitant alone and in
Aprepitant plus ondansetron compared with ondansetron alone in reducing
postoperative nausea and vomiting in ambulatory patients undergoing plastic
outpatient plastic surgery... CONCLUSION: In patients undergoing plastic surgery, the addition of aprepitant to
Aprepitant Plus Ondansetron Compared to Ondansetron Alone in Reducing Postoperative Nausea and Vomiting in Ambulatory Patients Undergoing Plastic Surgery. [2011.10.07]
BACKGROUND:: Postoperative nausea and vomiting (PONV) is a major challenge in the peri-operative setting. The incidence can be as high as 80%, and the majority of PONV symptoms among out-patients occur after discharge. This study evaluated the efficacy of an NK1 receptor antagonist (aprepitant) in reducing PONV for up to forty-eight hours in patients undergoing outpatient plastic surgery... CONCLUSIONS:: In patients undergoing plastic surgery, the addition of aprepitant to ondansetron significantly decreases postoperative vomiting rates and nausea severity for up to 48 hours postoperatively. LEVEL OF EVIDENCE:: Level 2 single-centered prospective randomized controlled therapeutic trial.
Clinical Trials Related to Emend (Aprepitant)
Efficacy of Aprepitant (Emend´┐Ż) in Children [Not yet recruiting]
The purpose of this study is to find out whether or not adding aprepitant(Emend«) to the
standard therapy will help children who receive chemotherapy to have less nausea and
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134 AM3) [Recruiting]
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for
the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0
months to 17 years of age.
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Under 18 Years of Age (MK-0517-029 AM3) [Recruiting]
The purpose of this study is to determine the appropriate dosing regimen of fosaprepitant,
when administered with ondansetron (with or without dexamethasone), for the prevention of
CINV in children from birth to 17 years of age. Fosaprepitant is a prodrug to aprepitant.
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide [Not yet recruiting]
The objectives of the study are: 1) to assess the Chemotherapy Induced Nausea and Vomiting
(CINV) efficacy and toxicity of Aprepitant in combination with Ondansetron vs Ondansetron
alone in preventing acute CINV in brain tumor patients during the acute period (first 24
hours) of receiving 5 day temozolomide therapy; and 2) to assess the efficacy of Aprepitant
in combination with Ondansetron vs Ondansetron alone in preventing delayed CINV (day 2-5).
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial [Recruiting]
The object of this study is to evaluate the superiority of aprepitant therapy with a
5HT3-receptor antagonist, dexamethasone and aprepitant compared to standard therapy with a
5HT3-receptor antagonist and dexamethasone for prevention of nausea and vomiting in first
Reports of Suspected Emend (Aprepitant) Side Effects
Drug Interaction (16),
Renal Failure Acute (14),
Septic Shock (9), more >>